IFN-α2 Antibody (NYRhIFN-α): sc-73305

IFN-α2 Antibody (NYRhIFN-α) is a mouse monoclonal IgG1 antibody that detects IFN-α2 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IFN-α2, a member of the type I interferon family, plays a crucial role in the immune response by modulating the activity of immune cells and enhancing the antiviral state of neighboring cells. This cytokine is particularly important for activating natural killer cells and promoting the expression of major histocompatibility complex (MHC) molecules, which are essential for the presentation of viral antigens to T cells. The effective functioning of IFN-α2 is vital in controlling viral infections and has therapeutic implications in treating various malignancies and autoimmune disorders. Additionally, IFN-α2′s structure, characterized by a unique four-helix bundle, is critical for interaction with the type I interferon receptor, which is a multisubunit complex that mediates the diverse biological effects of interferons. Anti-IFN-α2 antibody (NYRhIFN-α) is an invaluable tool for researchers studying the intricate roles of interferons in immune regulation and their potential in clinical applications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IFN-α2 Antibody (NYRhIFN-α) References:

1. Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta.  |  Platis, D. and Foster, GR. 2003. J Interferon Cytokine Res. 23: 655-66. PMID: 14651780
2. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.  |  Leaman, DW., et al. 2003. J Interferon Cytokine Res. 23: 745-56. PMID: 14769151
3. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.  |  Bekisz, JB., et al. 1989. J Interferon Res. 9 Suppl 1: S1-7. PMID: 2809275
4. A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.  |  Saleh, MI. and Hindi, NN. 2018. Naunyn Schmiedebergs Arch Pharmacol. 391: 953-963. PMID: 29872876
5. The potency of interferon-alpha 2 and interferon-gamma in a combination therapy of dendritic keratitis. A controlled clinical study.  |  Sundmacher, R., et al. 1987. Curr Eye Res. 6: 273-6. PMID: 3030650
6. Interleukin-17A Facilitates Chikungunya Virus Infection by Inhibiting IFN-α2 Expression.  |  Neupane, B., et al. 2020. Front Immunol. 11: 588382. PMID: 33304351
7. NFKB2 haploinsufficiency identified via screening for IFN-α2 autoantibodies in children and adolescents hospitalized with SARS-CoV-2-related complications.  |  Bodansky, A., et al. 2023. J Allergy Clin Immunol. 151: 926-930.e2. PMID: 36509151
8. Interferon alpha-2 for hairy cell leukemia: evidence for induction of RNA synthesis in hairy cells and failure to correlate enhancement of natural killer cells with elimination of hairy cells.  |  Schwarzmeier, JD., et al. 1987. Eur J Haematol. 39: 418-25. PMID: 3691760
9. Clinical and in vitro antiproliferative properties of recombinant DNA-derived human interferon-alpha 2.  |  Freedman, MH., et al. 1986. Am J Pediatr Hematol Oncol. 8: 178-82. PMID: 3766908
10. Differential effects of interferon-alpha 2 and interleukin-2 on natural killer cell activity in patients with acquired immune deficiency syndrome.  |  Reddy, MM., et al. 1984. J Biol Response Mod. 3: 379-86. PMID: 6332880

The preferred IFN-α2 antibody is IFN-α2 Antibody (MT4/E4): sc-53342.